Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.
about
Metformin Decouples Phospholipid Metabolism in Breast Cancer CellsResponse evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatmentCurrent opportunities and challenges of magnetic resonance spectroscopy, positron emission tomography, and mass spectrometry imaging for mapping cancer metabolism in vivo.Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy.Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.Probing the PI3K/Akt/mTor pathway using (31)P-NMR spectroscopy: routes to glycogen synthase kinase 3.Textural features of 18F-FDG PET after two cycles of neoadjuvant chemotherapy can predict pCR in patients with locally advanced breast cancer.Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
P2860
Q28550634-BA2B8ED5-46D1-43C2-AAFA-32CCF66162A8Q35539538-A6462803-5D01-48C3-8192-C1A0BC1AECEEQ36557319-85FF3442-AD85-4D17-A90C-00947BBD921AQ37185872-9075FCAC-2032-4DDF-9E48-CD4589F15E6EQ37644820-348ED768-D5CB-4F63-82E4-84F7F22F936CQ38132274-877B5ED8-DA07-44BD-B225-D61B53205D12Q39024453-30D20F43-0715-4898-8005-25ADC43E678BQ42120404-AFC4E467-A083-4EF3-BC9B-DA0AAEAFB5A0Q47990268-B32AA1FF-38B8-4C6E-B381-F7076EF2AA1BQ53026369-F199C82B-B38F-47D0-AD95-CB9AD784FA21
P2860
Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Response to trastuzumab by HER ...... -detectable phosphomonoesters.
@en
Response to trastuzumab by HER ...... -detectable phosphomonoesters.
@nl
type
label
Response to trastuzumab by HER ...... -detectable phosphomonoesters.
@en
Response to trastuzumab by HER ...... -detectable phosphomonoesters.
@nl
prefLabel
Response to trastuzumab by HER ...... -detectable phosphomonoesters.
@en
Response to trastuzumab by HER ...... -detectable phosphomonoesters.
@nl
P2093
P2860
P1476
Response to trastuzumab by HER ...... R-detectable phosphomonoesters
@en
P2093
Alastair M Thompson
Ian N Fleming
Karen Murray
M Virginia C L Appleyard
Sheila Sharp
P2860
P2888
P304
P356
10.1007/S00280-012-2032-6
P577
2012-11-24T00:00:00Z